This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
n11http://dx.doi.org/10.1136/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q91233537
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu en payares de 2019 scientific article published on 11 November 2019 wetenschappelijk artikel 2019 թվականի նոյեմբերի 11-ին հրատարակված գիտական հոդված article scientifique publié en 2019 наукова стаття, опублікована 11 листопада 2019
p:P577
wds:Q91233537-199F091C-4E68-4395-B3B6-9065F2ADAF28
wdt:P577
2019-11-11T00:00:00Z
p:P2093
wds:Q91233537-2CEDCB69-0A65-44F3-9992-880A5B396031
wdt:P2093
Evangelia Samoli
rdfs:label
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
skos:prefLabel
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
schema:name
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
p:P50
wds:Q91233537-9A3DEBF2-EA9F-477F-994A-A2FA7952F25F wds:Q91233537-18D1BE2A-AA96-4C50-8342-CD3727C0C912 wds:Q91233537-1D85D16C-D79E-43A0-AC15-734117F91822
wdt:P50
wd:Q91233526 wd:Q57034988 wd:Q91233531
p:P1476
wds:Q91233537-9654DAF4-C367-4AD1-AC6C-FE78A844D90F
wdt:P1476
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
p:P304
wds:Q91233537-309BC85C-F878-4018-8598-C35937AFE8D5
wdt:P304
304-307
p:P31
wds:Q91233537-73DBBE1C-8BA4-48D5-93CE-C3B3A3ECC1C1
wdt:P31
wd:Q13442814
p:P921
wds:Q91233537-D58EB879-C72D-4BAE-99E8-7D06BD16A267 wds:Q91233537-DE35ABD8-7249-414F-8D90-DA240227A11D wds:Q91233537-B78C18E7-B4EB-435B-BC0A-98BDE0C9004A
wdt:P921
wd:Q1485 wd:Q1996249 wd:Q269829
p:P698
wds:Q91233537-687112C0-22C6-4139-9F35-E79F3DC0292F
wdtn:P698
n9:31712248
wdt:P698
31712248
p:P1433
wds:Q91233537-0660AF84-872E-4EC0-A1A0-75688488F659
wdt:P1433
wd:Q4767876
p:P433
wds:Q91233537-503DD89D-1EDD-40E7-A108-618CDD944073
p:P478
wds:Q91233537-EC0CEBD1-4B97-41EE-8AA1-F335D19509FA
wdt:P433
2
wdt:P478
79
p:P356
wds:Q91233537-360AFFD9-A828-4670-9990-AFD70CC03D73
wdtn:P356
n11:ANNRHEUMDIS-2019-216367
wdt:P356
10.1136/ANNRHEUMDIS-2019-216367